Mineralys Shares Plunge 12% After Pricing $150M Stock Offering
Summary
Mineralys Therapeutics shares fell 12% after the company priced a $150 million common stock offering at $26.50 per share. This capital raise, which is dilutive to existing shareholders, is intended to fund a portion of a $200 million upfront payment to repurchase royalty obligations for its lead drug, lorundrostat. The offering follows the company's earlier announcement today of a $500 million committed debt facility and securing full intellectual property rights for lorundrostat, as detailed in a recent 8-K. The market reacted negatively to the financing structure despite the strategic move to consolidate IP and secure funding for its pipeline. The FDA PDUFA date for lorundrostat is December 17, 2026.
At the time of this announcement, MLYS was trading at $25.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $12.59 to $47.65. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.